Literature DB >> 8816384

Distribution of IL-15 receptor alpha-chains on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression.

D W Chae1, Y Nosaka, T B Strom, W Maslinski.   

Abstract

IL-15, a newly described cytokine exerting IL-2-like in vitro activities, binds to and induces proliferation of cells co-expressing IL-15R alpha, IL-2R beta, and IL-2R gamma chains. To study the expression of human IL-15R alpha chains, we have utilized tagged human IL-15 protein and FACS analysis. In contrast to resting cells, mitogen-activated macrophages, NK cells, and CD4+ and CD8+ T cells express IL-15R alpha chains. Neither IL-2R alpha nor IL-2R beta chains are required for IL-15 binding. Dexamethasone, but not cyclosporine or rapamycin, blocks mitogen-induced IL-15R alpha expression. Dexamethasone-pretreated cells respond to IL-15 poorly, while the response to IL-2 is not affected. Thus, despite structural and functional similarities between IL-2R alpha and IL-15R alpha chains, the activation-triggered mechanisms of induction are different. Since IL-15R alpha chain is necessary and sufficient for IL-15 binding, regulation of IL-15R alpha expression may represent a new target for T cell-directed pharmacologic intervention.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816384

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Reactivation of tuberculosis is associated with a shift from type 1 to type 2 cytokines.

Authors:  A D Howard; B S Zwilling
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Addition of an IL-15 mutant/FCgamma2A antagonist protein protects islet allografts from rejection overriding costimulation blockade.

Authors:  S Ferrari-Lacraz; X X Zheng; Y S Kim; W Maslinski; T B Strom
Journal:  Transplant Proc       Date:  2002-05       Impact factor: 1.066

3.  Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity.

Authors:  Y S Kim; W Maslinski; X X Zheng; A C Stevens; X C Li; G H Tesch; V R Kelley; T B Strom
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

4.  Interleukin-15 activates proinflammatory and antimicrobial functions in polymorphonuclear cells.

Authors:  T Musso; L Calosso; M Zucca; M Millesimo; M Puliti; S Bulfone-Paus; C Merlino; D Savoia; R Cavallo; A N Ponzi; R Badolato
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction.

Authors:  A Ahmad; E Sharif-Askari; L Fawaz; J Menezes
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 6.  Location and cellular stages of natural killer cell development.

Authors:  Jianhua Yu; Aharon G Freud; Michael A Caligiuri
Journal:  Trends Immunol       Date:  2013-09-19       Impact factor: 16.687

7.  An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection.

Authors:  S Ferrari-Lacraz; X X Zheng; Y S Kim; Y Li; W Maslinski; X C Li; T B Strom
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

8.  IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses.

Authors:  Yvonne M Mueller; Duc H Do; Susan R Altork; Carol M Artlett; Edward J Gracely; Christos D Katsetos; Agustin Legido; Francois Villinger; John D Altman; Charles R Brown; Mark G Lewis; Peter D Katsikis
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

9.  Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2006-03-07       Impact factor: 4.599

10.  Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection.

Authors:  Matthew D Eberly; Muhamuda Kader; Wail Hassan; Kenneth A Rogers; Jianzhong Zhou; Yvonne M Mueller; Mary J Mattapallil; Michael Piatak; Jeffrey D Lifson; Peter D Katsikis; Mario Roederer; Francois Villinger; Joseph J Mattapallil
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.